API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2022/12/13/2572358/0/en/Spexis-announces-promising-pre-clinical-data-with-balixafortide-in-combination-with-various-therapies-on-the-market-for-treating-B-cell-lymphomas.html
https://www.globenewswire.com/news-release/2022/12/13/2572358/0/en/Spexis-announces-promising-pre-clinical-data-with-balixafortide-in-combination-with-various-therapies-on-the-market-for-treating-B-cell-lymphomas.html
https://www.globenewswire.com/news-release/2022/09/22/2520691/0/en/Spexis-announces-positive-renal-impairment-clinical-trial-results-with-balixafortide.html
https://www.bloomberg.com/press-releases/2021-07-16/eqs-adhoc-polyphor-provides-update-on-the-future-of-the-fortress-study-of-balixafortide-and-announces-initial-restructuring
https://www.fiercebiotech.com/biotech/polyphor-flops-a-phase-3-jeopardizing-its-future-as-shares-more-than-halved
https://www.globenewswire.com/news-release/2021/06/28/2253544/0/en/Polyphor-Provides-Update-on-the-Phase-III-FORTRESS-Study-of-Balixafortide-in-Patients-With-Advanced-HER2-Negative-Breast-Cancer.html
https://www.globenewswire.com/news-release/2020/12/14/2144199/0/en/Polyphor-Announces-Third-Positive-Data-Safety-Monitoring-Board-DSMB-Recommendation-to-Continue-Phase-III-balixafortide-FORTRESS-Study-Without-Modifications.html
https://www.pharmiweb.com/press-release/2020-10-30/polyphor-completes-recruitment-in-phase-iii-trial-of-balixafortide-in-metastatic-breast-cancer